Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)

W. Mendling; K. Friese; I. Mylonas; E.-R. Weissenbacher; J. Brasch; M. Schaller; P. Mayser; I. Effendy; G. Ginter-Hanselmayer; H. Hof; O. Cornely; M. Ruhnke

doi:10.1055/s-0035-1545741

GebFra - DGGG-Gesellschaftsausgaben, Table of Contents

Geburtshilfe Frauenheilkd 2015; 75(4): 342-354
DOI: 10.1055/s-0035-1545741

Guideline

GebFra Science

Georg Thieme Verlag KG Stuttgart · New York

Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)

Die Vulvovaginalkandidose (außer chronisch mukokutaner Kandidose). Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (AWMF-Registernummer 015/072, S2k-Level, Dezember 2013)

W. Mendling

¹Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Wuppertal

,

K. Friese

²Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München

,

I. Mylonas

²Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München

,

E.-R. Weissenbacher

³Premium Medizin, München

,

J. Brasch

⁴Universitätsklinikum Kiel, Klinik für Dermatologie, Kiel

,

M. Schaller

⁵Universitäts-Hautklinik Tübingen, Tübingen

,

P. Mayser

⁶Universitätsklinikum Giessen, Klinik für Dermatologie, Venerologie und Allergologie, Giessen

,

I. Effendy

⁷Klinikum Bielefeld, Hautklinik, Bielefeld

,

G. Ginter-Hanselmayer

⁸Universitätsklinik für Dermatologie und Venerologie Graz, Graz, Österreich

,

H. Hof

⁹Labor Limbach, Heidelberg

,

O. Cornely

¹⁰Uniklinik Köln, Klinik I für Innere Medizin, Köln

,

M. Ruhnke

¹¹Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité, Berlin

› Author Affiliations

Abstract

Full Text

References

References
1 Aballéa S, Guelfucci F, Wagner J et al. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes 2013; 11: 169-173
2 Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291: 1368-1379
3 Auger P, Joly J. Microbial flora associated with candida albicans vulvovaginitis. Am J Obstet Gynecol 1980; 55: 397-401
4 Auler ME, Morreiva D, Rodriguez FF et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol 2010; 48: 211-216
5 Babula O, Lazdane G, Kroica J et al. Frequency of interlenkin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannosebinding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258-1262
6 Beigi RH, Meyn LA, Moore DM et al. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004; 104: 926-930
7 de Bernardis F, Agatensi L, Ross IK et al. Evidence for a role for secretory asparatate proteinase of Candida albicans in vulvovaginal candidosis. J Infect Dis 1990; 161: 1276-1283
8 de Bernardis F, Boccanera M, Cassone A. The Role of Immunity against vaginal Candida Infection. In: Fidel PL, Huffnagle GB, eds. Fungal Immunity: from an Organ Perspective. Heidelberg, New York: Springer; 2005: 345-355
9 Bisschop MP, Merkus JM, Scheygrond H et al. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986; 93: 79-81
10 Blaschke-Hellmessen R. Subpartale Übertragung von Candida und ihre Konsequenzen. Vertical transmission of candida and its consequences. Mycoses 1998; 41 (Suppl. 02) 31-36
11 Blaschke-Hellmessen R. Epidemiologische Untersuchungen zum Vorkommen von Hefepilzen bei Kindern und deren Müttern. Mykosen 1968; 11: 611-616
12 Bohanna NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 1998; 21: 451-456
13 Bond CM, Watson MC. Grampian Evidence Based Community Pharmacy Guidelines Group. The development of evidence-based guidelines for over-the-counter treatment of vulvovaginal candidiasis. Pharm World Sci 2003; 25: 177-181
14 Buch A, Skytte Christensen E. Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. Acta Obstet Gynecol Scand 1982; 61: 393-396
15 della Casa V, Noll H, Gonser S et al. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforsch 2002; 52: 699-705
16 Cassone A, de Bernardis F, Mondell F et al. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777-782
17 Cassone A, de Bernardis F, Torososantucci A. An outline of the role of anti-candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 2005; 5: 377-382
18 Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol 2012; 4: 427-433
19 Cetin M, Ocak S, Gungoren A et al. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis 2007; 39: 584-588
20 Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 1997; 176: 828-830
21 Chassot F, Negri MF, Swidsinski AF et al. Can intrauterine contraceptive devices be a Candida albicans reservoir?. Contraception 2008; 77: 355-359
22 Cohen L. Is more than one application of an antifungal necessary in the treatment of an acute vaginal candidosis?. Am J Obstet Gynecol 1985; 152: 961-964
23 Corsello S, Spinillo A, Osnengo G et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-72
24 Czeizel AE, Tóth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999; 10: 437-440
25 Czeizel AE, Fladung B, Varga P. Preterm birth reduction after clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 116: 157-163
26 Czeizel AE, Puhó EH, Kazy Z. The use of data set of the Hungarian case-control surveillance of congenital abnormalities for evaluation of birth outcomes beyond birth defects. Centr Eur J Public Health 2007; 15: 147-153
27 Davidson F, Mould RF. Recurrent vaginal candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 1978; 54: 176-183
28 Davidson F, Oates JK. The pill does not cause ‘thrush’. Br J Obstet Gynaecol 1985; 92: 1265-1266
29 Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 2001; 41: 326-328
30 Donders G, Babula O, Bellen G et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115: 1223-1231
31 Donders G, Bellen G, Byttebier G et al. Individualized decreasing dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199: 613.e1-613.e9
32 Donders G, Prenen H, Verbeke G et al. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002; 187: 989-993
33 Donders GG, Bellen G, Mendling W. Management of recurrent vulvovaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010; 70: 306-321
34 Eckert LO, Hawes SE, Stevens CE et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92: 757-765
35 Ehrström SM, Kornfeld D, Thuresson J et al. Signs of chronic stress in women with recurrent candida vulvovaginitis. Am J Obstet Gynecol 2005; 193: 1376-1381
36 Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006; 58: 266-272
37 Farmer MA, Taylor AM, Bailey AL et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med 2011; 3: 101ra91
38 Farrell SM, Hawkins DF, Ryder TT. Scanning electron microscope study of Candida albicans, invasion of cultural human cervical epithelial cells. Sabouraudia 1983; 25: 251-254
39 Ferris GD, Nyirjesy P, Sobel JD et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99: 419-425
40 Ferwerda B, Ferwerda B, Platinga TS et al. Human lectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760-1767
41 Fidel jr. PL. Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005; 18: 107-111
42 Fidel jr. PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96
43 Fong JW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med 1992; 68: 374-377
44 Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990; 80: 329-331
45 Foxman B, Muraglia R, Dietz JP et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. Low Genit Tract Dis 2012; 17: 1-6
46 Friese K, Neumann G, Siebert J. Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 2003; 268: 194-197
47 Frey Tirri B. Antimicrobial topical agents used in the vagina. Curr Probl Dermatol 2011; 40: 36-47
48 Gaspard U, Scheen A et al. Randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabilism. Contraception 2003; 67: 423-429
49 Geraldo P, Neuer A, Korneeva IL et al. Vaginal heat shock protein expression in symptom-free women with history of recurrent vulvovaginitis. Am J Obstet Gynecol 1999; 180: 524-529
50 Ghannoum MA, Abu-Elteen KH. Pathogenicity determinants of Candida. Mycoses 1990; 33: 265-282
51 Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122-143
52 Goswami R, Dadhwal V, Tejaswi S et al. Species-specific prevalence of vaginal candidiasis amoung patients with diabetes mellitus and its relation to their glycaemic status. J Infect Dis 2000; 41: 162-166
53 Goswami D, Goswami R, Banerjee U et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 2006; 52: 111-117
54 Hay PH, Czeizel AE. Asymptomatic trichomonas and candida colonization and pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007; 21: 403-409
55 Hettiarachchi N, Ashbee HR, Wilson JD. Prevalence and management of non-albicans vaginal candidiasis. Sex Transm Infect 2010; 86: 99-100
56 Hilton E, Isenberg HD, Alperstein P et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116: 353-357
57 Hoffstetter SE, Barr S, LeFevre C et al. Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting. J Reprod Med 2008; 53: 402-406
58 Holland S, Vinh D. Yeast infections – human genetics in the rise. N Engl J Med 2009; 361: 1798-1801
59 Ip WK, Lan YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190: 632-640
60 Ismail A, Lupan DM. Utilisation of siderophores by Candida albicans. Mycopath 1986; 96: 109-113
61 Jeavons HS. Prevention and treatment of vulvovaginal candidosis using exogenous lactobacilli. J Obstet Gynecol Neonatal Nurs 2003; 32: 287-296
62 De Jong MA, Vriend LE, Theelen B et al. C-type lectin Langerhans is a beta-glucan receptor on human Langerhans cells that recognize opportunistic and pathogenic fungi. Mol Immunol 2010; 47: 1216-1225
63 Kiss H, Petricevicz L, Husslein P. Prospective randomised controlled trial of an infection screening program to reduce the rate of preterm delivery. BMJ 2004; 329: 371-375
64 Koldowsky H, Kariger U, Mendling W. Herstellung eines autologen membrangebundenen Candida-Antigens und in-vitro-Untersuchungen zu seinen immunologischen Reaktionen. In: Metzner G, Weissenbacher ER, Hrsg. Candida-Infektionen des weiblichen Genitaltraktes. München: Medifact; 1999: 25-32
65 Kunzelmann V, Tietz HJ, Roßner D et al. Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalkandidosen. Mycoses 1996; 39 (Suppl. 01) 65-72
66 Lattif AA, Prasard R et al. The glyzolate cycle enzyme activities in the pathogenitic isolates of Candida albicans obtained from HIV/AIDS, diabetic and burn patients. Mycoses 2006; 49: 85-89
67 de Leon E, Jacober SJ, Sobel JD et al. Prevalence and risk factors for vaginal Candida colonization in women with type I and type 2 diabetes. BMC Infect Dis 2002; 2: 1-6
68 Li J, Fan SR, Liu XP et al. Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China. Clin Infect Dis 2008; 47: 1119-1125
69 Loeffler W. Terminologie der Humanmykosen. Mykosen 1983; 26: 346
70 Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe labaratory standard. Obstet Gynecol 2009; 113: 89-95
71 Mailänder-Sánchez D, Wagener J et al. Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. Mycoses 2012; 55: 17-26
72 Martinez RC, Seney SL, Summers KL et al. Effect of Lactobacillus rhamsosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and incluce inflammation. Microbiol Immunol 2009; 53: 487-495
73 Mastroiacovo P, Mazzone T, Botto LD. Prospective assessment of pregnancy outcome after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 176: 1645-1650
74 Mathema B, Cross E, Dun E et al. Prevalence of vaginal colonization by drug-resistent candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001; 33: E23-E27
75 Meinhof W. Die Salzsäure-Toleranz von Candida albicans. Mykosen 1974; 17: 339-347
76 Mendling W. Die Torulopsidose in der Frauenheilkunde. Geburtsh Frauenheilk 1984; 44: 583-586
77 Mendling W. Azoles in the Therapy of vaginal Candidosis. In: Berg D, Plempel M, eds. Sterol Biosynthesis Inhibitors. Chichester: Ellis Horwood; 1988: 480-506
78 Mendling W, Koldovsky U. Investigations by cell-mediated immunologic tests of therapeutic trials with thymopentin in vaginal mycoses. Infect Dis Obstet Gynecol 1996; 4: 225-231
79 Mendling W, Gutschmidt J, Gantenberg R et al. Vergleich der Stammspezifität von Hefepilzen verschiedener Lokalisationen bei Frauen mit Vaginalcandidosen und deren Partnern. Mycoses 1998; 41 (Suppl. 02) 22-25
80 Mendling W, Krauss C, Fladung B. A clinical multi-center-study comparing afficacy and tolerability of topical combination therapy with Clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. Mycoses 2004; 47: 136-142
81 Mendling W, Niemann D, Tintelnot K. Vaginal colonisation with Candida species with special focus on Candida dubliniensis. A prospective study. Geburtsh Frauenheilk 2007; 67: 1132-1137
82 Mendling W, Seebacher C. Vulvovaginalkandidose. AWMF-Guideline 013/004 (S1). 2008.
83 Mendling W. Vaginose, Vaginitis, Zervizitis und Salpingitis. 2. Aufl.. Heidelberg: Springer; 2006
84 Mendling W, Spitzbart H. Antimykotische Therapie der vaginalen Hefepilz-Kolonisation von Schwangeren zur Verhütung von Kandidamykosen beim Neugeborenen. AMWF, Guideline 015/042 (S1). 2008.
85 Mendling W, Birkner V. Die Vakzination mit inaktivierten Laktobazillen oder Heliotherapie kann die Lebensqualität von Frauen mit chronisch rezidivierender vulvovaginaler Kandidose verbessern. – Eine prospektive, 3-armige randomisierte Studie. Geburtsh Frauenheilk 2011; 71: 767-772
86 Mendling W, Schlegelmilch R. Three-day combination treatment for vulvovaginal Candidosis with 200 mg clotrimazol vaginal suppositories and clotrimazol cream for the vulva is significantly better than treatment with vaginal suppositories alone – an earlier, multi-centre, placebo-controlled double blind study. Geburtsh Frauenheilk 2014; 74: 355-360
87 Meyer H, Göttlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006; 48: 202-209
88 Molgaard-Nielsen D, Pasternak B, Hviid A. Use of fluconazole during pregnancy and risk of birth defects. N Engl J Med 2013; 369: 830-839
89 Moraes PSA, de Lima Goiaba S, Taketoni EA. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. J Investig Allergol Clin Immunol 2000; 10: 305-309
90 Müller J, Nold B, Kubitza D et al. Quantitative Untersuchungen über die Döderlein-Flora gesunder sowie mykosekranker Probandinnen unter lokaler Isoconazol-Nitrat-Therapie. In: Seeliger HPR, Hrsg. Gyno – Travogen, Monographie Excerpta Medica. Amsterdam: Oxford Princeton; 1981: 81-93
91 Mylonas I, Bergauer F. Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method. Obstet Gynecol Surv 2011; 66: 359-368
92 Naglik J, Albrecht A, Bader O et al. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6: 915-926
93 Neves NA, Carvallho LP, de Oliveira MA et al. Association between atopy and recurrent vaginal candidosis. Clin Exp Immunol 2005; 142: 167-171
94 Niewerth M, Kunze D, Seibold M et al. Ciclopirox olamine treatment affects the expression pattern of metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1805-1817
95 Nurbhai M, Grimshaw J, Watson M et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007; (4) CD002845
96 Nyirjesy P, Seeney SM, Grody MH et al. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995; 173: 820-823
97 Nyirjesy P, Alexander AB, Weitz MV. Vaginal candida parapsilosis: pathogen or bystander?. Infect Dis Obstet Gynecol 2005; 13: 37-41
98 Odds FC. Candida and Candidosis. 2nd. ed. Bailliére Tindall: WB Saunders; 1988
99 Odds FC, Arai T, Disalvo AF et al. Nomenclature of fungal diseases: a report and recommendations from a sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992; 30: 1-10
100 Paulitsch A, Weger W, Ginter-Hanselmayer G et al. A 5-year (2000–2004) epidemiological survey of Candida and non-candida yeasts species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006; 49: 471-475
101 Phillips AJ. Treatment of non-albicans candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192: 2009-2012
102 Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Womenʼs experience of post-antibiotic vulvovaginitis. Med J Aust 2003; 179: 43-46
103 Pirotta M, Gunn J, Chondros P et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004; 329: 548-551
104 Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006; 44: 3213-3217
105 Pitsoni E, Lavazzo C, Falagas ME. Itraconazole vs. fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomised controlled trials. Am J Obstet Gynecol 2008; 198: 153-160
106 Plempel M. Pharmakokinetik der Imidazol-Antimykotika. Mykosen 1980; 23: 16-27
107 Powell BL. Identification of a 173-estradiol-bindig protein in Candida albicans and Candida (Torulopsis) glabrata. Exp Mycology 1984; 8: 304
108 Quereux C, Gelas B, Chevallier T et al. Evaluation of the efficacy and speed of action of sertoconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil 2000; 28: 238-244
109 Ray D, Goswami R, Bomerjee U et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30: 312-317
110 Raska M, Belakova J, Horynova M et al. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008; 46: 411-420
111 Reed BD, Zazone P, Pierson LL et al. Candida transmission and sexual behaviour as risk for a repeated episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003; 12: 979-989
112 Richter SS, Galask RP, Messer SA et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162
113 Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvo-vaginitis treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162: 332-336
114 Ritter W. Pharmacokinetics of Azole Compounds. In: Berg D, Plempel M, eds. Sterol Biosynthesis Inhibitors. Chichester: Ellis Horwood; 1988: 397-429
115 Roberts CL, Rickard K, Kotsiou G et al. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial. BMC Pregnancy Childbirth 2011; 11: 18
116 Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11: 275-288
117 Romeo O, Criseo G. Candida africana and its closest relatives. Mycoses 2011; 54: 475-486
118 Rosedale N, Browne K. Hyposensitisation in the management of recurring vaginal candidiasis. Ann Allergy 1979; 43: 250-253
119 Roth AC, Milsom I, Forssman L et al. Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourin Med 1990; 66: 357-360
120 Rüchel R, Fegeler R, Trost M. Comparison of secretory proteinases from different strains of Candida albicans. Sabouraudia 1982; 20: 233-244
121 Rusch K, Schwiertz A. Candida autovaccination in the treatment of vulvovaginal Candida infections. Int J Gynecol Obstet 2007; 96: 130
122 Rylander E, Berglund A-L, Krassny C et al. Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004; 80: 54-57
123 Savini V, Catavitello C, Manua A et al. Two cases of vaginitis caused by Itraconazole – resistant Saccharomyces cerevisiae and review of recently published studies. Mycopathologia 2008; 166: 47-50
124 Scheklakow ND, Deletorski WW, Goldoa OA. Veränderungen der Ultrastruktur von Candida albicans unter Einwirkung von Polyen-Antibiotika. Mykosen 1980; 24: 140-152
125 Schnell JD. Epidemiology and prevention of peripartal mycoses. Chemotherapy 1982; 28 (Suppl. I) 66-72
126 Schnell JD, Voigt WH. Das Verhalten von Sprosspilzen am nicht verhornenden Plattenepithel. Arch Gynaekol 1974; 217: 377-382
127 Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009; 64: 354-356
128 Sharma C, Muralidhar S, Xu J et al. Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India. Mycoses 2014; 57: 544-552
129 Singh S, Sobel JD, Bhargava P et al. Vaginitis due to candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002; 35: 1066-1070
130 Sobel JD. Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol 1985; 65: 435-440
131 Sobel JD. Vaginitis due to Saccharomyces cereviseae: epidemiology, clinical aspects, and therapy. Clin Infect Dis 1993; 16: 93-99
132 Sobel JD. Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998; 41 (Suppl. 02) 18-21
133 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-1971
134 Sobel JD, Harold C, Wiesenfeld MD et al. Maintenance fluconazole therapy for recurrent vulvovaginal Candidiasis. N Engl J Med 2004; 351: 876-883
135 Sobel JD, Myers PG, Kaye D et al. Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis 1981; 143: 76-82
136 Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38
137 Spacek J, Jilek P, Buchta V et al. The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses 2005; 48: 391-395
138 Spinillo A, Capuzzo E, Egbe TO et al. Torulopsis glabrata vaginitis. Obstet Gynecol 1995; 85: 993-998
139 Swidsinski A, Loening-Baucke V, Mendling W et al. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol Histopathol 2014; 29: 567-587
140 Tarry W, Fisher M, Shen S et al. Candida albicans: the estrogen target for vaginal colonization. J Surg Res 2005; 129: 278-282
141 Thoden J, Potthoff A, Bogner JR et al. Therapy and prophylaxis of the opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection 2013; 41 (Suppl. 02) S91-S115
142 Thrumbore DJ, Sobel JD. Recurrent vulvovaginal candidiasis: vaginal epithelial cells susceptibility to Candida albicans adherence. Obstet Gynecol 1986; 67: 810-812
143 Tietz HJ. Gezieltes Vorgehen gegen Problemkeime. Gyn Geburtsh 2009; 7–8: 41-44
144 Tietz HJ. Candida glabrata: Pathogenität und Stand der Dinge. Hautarzt 2012; 63: 868-871
145 Upmalis DH, Cone FL, Lamia CA et al. Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days. J. Womens Health Gend Based Med 2000; 9: 421-429
146 Vecciarelli A, Pericolini E, Pietrella D. New approaches in the development of a vaccine for mucosal Candidiasis: progress and challenges. Front Microbiol 2012; 3: 294
147 Vermitsky JP, Self MJ, Chadwick SG et al. Survey of vaginal flora–flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008; 46: 1501-1503
148 Wajnberg M, Wajnberg A. Doppelblind-Vergleichsstudie mit Ciclopyroxolamin- und Miconazol-Vaginalcreme bei vulvovaginaler Kandidose. Mykosen 1981; 24: 721-730
149 Walker PP, Reynolds MT, Ashbee HR et al. Vaginal yeasts in the era of “over the counter” antifungals. Sex Transm Infect 2000; 76: 437-438
150 Watson MC, Grimshaw JM, Bond CM et al. Oval versus intravaginal imidazole and triazole antifungal treatment of uncomplicated Candidiasis (thrush): a systemic review. BJOG 2002; 109: 85-89
151 Weissenbacher TM, Witkin SS, Gingelmaier A et al. Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol 2009; 144: 59-63
152 Weissenbacher T, Witkin SS, Ledger WJ et al. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009; 279: 125-129
153 van de Wijgert JH, Verwijs MC, Turner AN et al. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 2013; 27: 2141-2153
154 Wilson C. Recurrent vulvovaginal candidiasis; an overview of traditional and alternative therapies. Adv Nurse Pract 2005; 13: 24-29
155 Witkin SS, Jeremias J, Ledger WJ. A localized vaginal allergic response in women with recurrent vaginitis. J Allergy Clin Immunol 1988; 81: 412-416
156 Witkin SS, Giraldo P, Linhares D. New insights into the immune pathogenesis of recurrent vulvovaginal candidiasis. Int J Gynecol Obstet 2000; 3: 114-118
157 Witt A, Kaufmann U, Bitschnau M et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG 2009; 11: 1499-1505
158 Wozniak KL, Palmer G, Kutner R et al. Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. Med Mycol 2005; 43: 589-601
159 Xu J, Schwartz K, Bartoces M et al. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med 2008; 21: 261-268
160 Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; (4) CD000225
161 von Zglinicki W. Die Hormonspirale als Ursache für chronische Infektionen. Dissertation (Prof. HJ Tietz). Charité; 2011

Supplementary Material

German supporting information for this article